2001 B Cells,Human Lupus Biology
Dr. Gosselin aimed to generate a new monoclonal-antibody based therapeutic that would specifically block the production of harmful autoantibodies in lupus and other autoimmune diseases.
He successfully engineered the molecule and conducted preliminary tests in an artificial cell-based experimental system. The tests showed that the molecule can inhibit and kill human B cells.
In 2003, Gosselin published his findings in Human Antibodies, a specialist methodological journal.
Although the molecule was designed to block the production of harmful autoantibodies, Dr. Gosselin subsequently reported that it can enhance antibody responses in mice, which suggests that the molecule might have potential as a vaccine. But it also implies that the molecule may not be safe for lupus (or other autoimmune disease) treatment.
“This [LRI] work helped us develop our molecular strategies for generating antigen-antibody fusion proteins, which we still utilize currently to stimulate immunity,” reported Dr. Gosselin in 2010.
Generation of a human IgG3-streptavidin fusion protein. Implications for the inhibition and elimination of auto-reactive B cells. Hum Antibodies. 2003;12(3):77-92 Preissler MT, Walsh MC, Banas JA, Gallagher DJ, Gosselin EJ.
Enhanced antigen-specific antibody and cytokine responses when targeting antigen to human FcGAMMA receptor type I using an anti-human FcGAMMA receptor type I-streptavidin fusion protein in an adjuvant-free system. Immunol Invest. 2005;34(4):417-29. Adamova E, Walsh MC, Gosselin DR, Hale K, Preissler MT, Graziano RF, Gosselin EJ.
Rev. July 2010